How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,722 results for

macrolides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Ceftriaxone versus ceftriaxone plus a macrolide for community acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial. Full Text available with Trip Pro

Ceftriaxone versus ceftriaxone plus a macrolide for community acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial. To evaluate if treatment with ceftriaxone and a macrolide, improved patient outcome when compared with monotherapy with ceftriaxone, in hospitalized patients with human immunodeficiency virus/acquired immunodeficient syndrome (HIV/AIDS) with community-acquired pneumonia (CAP).Adult patients with HIV hospitalized due to suspected CAP were (...) randomized to receive one of two regimens, ceftriaxone plus macrolide or ceftriaxone plus placebo, at a 1:1 proportion (Brazilian Clinical Trials Registry: RBR-8wtq2b). The primary outcome was in-hospital mortality and the secondary outcomes were mortality within 14 days, need for vasoactive drugs, need for mechanical ventilation, time to clinical stability and length of hospitalization.A total of 227 patients were randomized, two were excluded after randomization; 225 patients were analysed (112

2017 Clinical Microbiology and Infection Controlled trial quality: predicted high

162. Acquired resistance to macrolides in <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients. Full Text available with Trip Pro

Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients. Cystic fibrosis (CF) patients receive chronic treatment with macrolides for their antivirulence and anti-inflammatory properties. We, however, previously showed that Pseudomonas aeruginosa, considered as naturally resistant to macrolides, becomes susceptible when tested in a eukaryotic medium rather than a conventional broth.We therefore looked for specific macrolide resistance determinants in 333 (...) CF isolates from four European CF centres in comparison with 48 isolates from patients suffering from hospital-acquired pneumonia (HAP).Minimum inhibitory concentrations (MICs) of macrolides and ketolides measured in eukaryotic medium (RPMI-1640) were higher towards CF than HAP isolates. Gene sequencing revealed mutations at three positions (2045, 2046 and 2598) in domain V of 23S rRNA of 43% of sequenced CF isolates, but none in HAP isolates. Enzymes degrading extracellular polymeric substances

2017 European Respiratory Journal

163. Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides. Full Text available with Trip Pro

Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides. Asthma is a chronic respiratory disease characterized by reversible airway obstruction and airway hyperresponsiveness to non-specific bronchoconstriction agonists as the primary underlying pathophysiology. The worldwide incidence of asthma has increased dramatically in the last 40 years. According to World Health Organization (WHO) estimates, over 300 million children

2017 Respiratory research

164. Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. (Abstract)

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. It was postulated that antibiotics including macrolides could be used for the secondary prevention of coronary heart disease but recent studies showed that macrolides increase the cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with macrolides regarding duration of effect and risk factors; and to explore the potential effect of statins for the prevention of cardiovascular (...) events as a result of macrolide use.Several electronic databases (PubMed, EMBASE, Cochrane library) were searched to identify eligible studies. Observational studies and randomized controlled trials that investigated the association between macrolides and cardiovascular events in adults aged ≥18 years were included. A meta-analysis was conducted to investigate the short- and long-term risks of cardiovascular mortality, myocardial infarction, arrhythmia, and stroke. Methodological quality was assessed

2017 Drug Safety

165. Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia. Full Text available with Trip Pro

Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia. With the emergence of macrolide resistance, concerns about the efficacy of macrolides for the treatment of Mycoplasma pneumoniae (MP) pneumonia in children have been raised. This study aimed to determine the effect of macrolide resistance on the outcome of children who were hospitalized with MP pneumonia.Between 2010 and 2015, we performed culture of MP from (...) nasopharyngeal samples obtained from children who were hospitalized with pneumonia at five hospitals in Korea. Macrolide resistance was determined by the analysis of 23S rRNA gene transition and the minimal inhibitory concentrations of four macrolides. Medical records were reviewed to analyze the clinical response to treatment with macrolides.MP was detected in 116 (4.8%) of the 2436 children with pneumonia. MP pneumonia was prevalent in 2011 and 2015. Of the 116 patients with MP pneumonia, 82 (70.7%) were

2017 BMC Infectious Diseases

166. New macrolide-lincosamide-streptogramin B resistance gene <i>erm</i>(48) on the novel plasmid pJW2311 in <i>Staphylococcus xylosus</i>. Full Text available with Trip Pro

New macrolide-lincosamide-streptogramin B resistance gene erm(48) on the novel plasmid pJW2311 in Staphylococcus xylosus. Whole-genome sequencing of Staphylococcus xylosus strain JW2311 from bovine mastitis milk identified the novel 49.3-kb macrolide-lincosamide-streptogramin B (MLSB) resistance plasmid pJW2311. It contained the macrolide resistance gene mph(C), the macrolide-streptogramin B resistance gene msr(A), and the new MLSB resistance gene erm(48) and could be transformed

2017 Antimicrobial Agents and Chemotherapy

167. Macrolides

Macrolides USE OF MACROLIDES IN PREGNANCY 0344 892 0909 USE OF MACROLIDES IN PREGNANCY (Date of issue: June 2017 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary The macrolide antibiotics include azithromycin, clarithromycin (...) , erythromycin, spiramycin and telithromycin. Macrolides have an antibacterial spectrum similar to that of penicillin and are thus considered an alternative in penicillin-allergic patients. Indications include sinusitis, otitis media, pharyngitis, tonsillitis, bronchitis, skin and soft tissue infection. Azithromycin is also used in the treatment of chlamydia, and clarithromycin in the eradication of Helicobacter pylori . The considerable data for macrolides as a class, and for erythromycin specifically, do

2014 UK Teratology Information Service

168. Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection (CDI) with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain, BI/NAP1/027. Full Text available with Trip Pro

Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection (CDI) with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain, BI/NAP1/027. Antibiotics have been shown to influence the risk of infection with specific Clostridium difficile strains as well as the risk of C. difficile infection (CDI). We performed a retrospective case-control study of patients infected with the epidemic BI/NAP1/027 strain in a U.S. hospital following recognition (...) of increased CDI severity and culture of stools positive by C. difficile toxin immunoassay. Between 2005 and 2007, 72% (103/143) of patients with first-episode CDIs were infected with the BI strain by restriction endonuclease analysis (REA) typing. Most patients received multiple antibiotics within 6 weeks of CDI onset (median of 3 antibiotic classes). By multivariate analysis, fluoroquinolone and macrolide exposure was more frequent among BI cases than among non-BI-infected controls (odds ratio

2015 Antimicrobial Agents and Chemotherapy

169. Macrolide antibiotics for cystic fibrosis. (Abstract)

Macrolide antibiotics for cystic fibrosis. Macrolide antibiotics may have a modifying role in diseases which involve airway infection and inflammation, like cystic fibrosis.To test the hypotheses that, in people with cystic fibrosis, macrolide antibiotics: 1. improve clinical status compared to placebo or another antibiotic; 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy.We searched (...) the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearching relevant journals and abstract books of conference proceedings.We contacted investigators known to work in the field, previous authors and pharmaceutical companies manufacturing macrolide antibiotics for unpublished or follow-up data (May 2010).Latest search of the Group's Cystic Fibrosis Trials Register: 09 February 2011.Randomised

2011 Cochrane

170. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults Full Text available with Trip Pro

Macrolide antibiotics and the risk of ventricular arrhythmia in older adults Many respiratory tract infections are treated with macrolide antibiotics. Regulatory agencies warn that these antibiotics increase the risk of ventricular arrhythmia. We examined the 30-day risk of ventricular arrhythmia and all-cause mortality associated with macrolide antibiotics relative to nonmacrolide antibiotics.We conducted a population-based retrospective cohort study involving older adults (age > 65 yr (...) ) with a new prescription for an oral macrolide antibiotic (azithromycin, clarithromycin or erythromycin) in Ontario from 2002 to 2013. Our primary outcome was a hospital encounter with ventricular arrhythmia within 30 days after a new prescription. Our secondary outcome was 30-day all-cause mortality. We matched patients 1:1 using propensity scores to patients prescribed nonmacrolide antibiotics (amoxicillin, cefuroxime or levofloxacin). We used conditional logistic regression to measure the association

2016 EvidenceUpdates

171. Statin-induced rhabdomyolysis, acute kidney injury, hospitalization or death associated with concurrent macrolide antibiotics prescription: a systematic review

Statin-induced rhabdomyolysis, acute kidney injury, hospitalization or death associated with concurrent macrolide antibiotics prescription: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

172. Long term macrolide antibiotics for the treatment of bronchiectasis in adults - an individual patient data meta-analysis

Long term macrolide antibiotics for the treatment of bronchiectasis in adults - an individual patient data meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

173. Extended Spectrum Macrolide

Extended Spectrum Macrolide Extended Spectrum Macrolide Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Extended Spectrum Macrolide (...) Extended Spectrum Macrolide Aka: Extended Spectrum Macrolide , Azithromycin , Zithromax , Clarithromycin , Biaxin , Telithromycin , Ketek From Related Chapters II. Pharmacokinetics: Half Life Clarithromycin: 5 hours Telithromycin: 10 hours Azithromycin: 68 hours III. Precautions Increasing resistance for most indications (see below) with Azithromycin (see below) interaction with Clarithromycin (see below) IV. Dosing: Azithromycin (Zithromax) Directions Take more than 1 hour before or 2 hours after food

2018 FP Notebook

174. Macrolide

Macrolide Macrolide Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Macrolide Macrolide Aka: Macrolide , Erythromycin From Related (...) organisms covered urealyticum ( ) species Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Macrolide." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications Erythromycin op. ointment ( (on 6/18/2017 at ) #1 tube for $4.00 $4.00 each #3 tubes for $10.00 $3.33 each erythromycin (on 5/17/2017 at ) ERYTHROMYCIN 0.5% EYE OINTMENT Generic $2.21 per gram

2018 FP Notebook

175. Colchicine intoxication and colchicine-induced rhabdomyolysis associated with concurrent macrolide antibiotics prescription: a systematic review

Colchicine intoxication and colchicine-induced rhabdomyolysis associated with concurrent macrolide antibiotics prescription: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

176. Efficacy of macrolides on acute asthma or wheezing exacerbation in children

Efficacy of macrolides on acute asthma or wheezing exacerbation in children Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

177. Macrolides for children with bronchiolitis: a systematic review and meta-analysis

Macrolides for children with bronchiolitis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

178. Macrolides usage as anti-inflammatory agents in the treatment of community acquired pneumonia and ventilator associated pneumonia: a systematic review

Macrolides usage as anti-inflammatory agents in the treatment of community acquired pneumonia and ventilator associated pneumonia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

179. Effect of antimicrobial exposure duration on development of antimicrobial resistance (AMR) for macrolide antibiotics: protocol for a systematic review with a network meta-analysis

Effect of antimicrobial exposure duration on development of antimicrobial resistance (AMR) for macrolide antibiotics: protocol for a systematic review with a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

180. Efficacy and safety of prolonged use of macrolide antibiotics versus placebo for moderate to severe COPD patientsÿ

Efficacy and safety of prolonged use of macrolide antibiotics versus placebo for moderate to severe COPD patientsÿ Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>